Literature DB >> 15625085

The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis.

Linda C Gilbert1, Janet Rubin, Mark S Nanes.   

Abstract

After menopause, increased tumor necrosis factor-alpha (TNF-alpha) stimulates bone resorption while inhibiting differentiation of new bone-forming osteoblasts (OB). TNF receptors, p55 and p75, signal similar intracellular pathways, but only p55 activates apoptosis. To evaluate the relationship between the TNF receptor mediating inhibition of OB differentiation and the role of apoptosis, marrow stromal cells (MSC) were cultured from mice deficient in either or both receptors. Cells grown in ascorbate and beta-glycerophosphate produce alkaline phosphatase and osteocalcin and mineralize matrix. Treatment of wild-type or p55(+/+)/p75(-/-) MSC with murine TNF (binds p55 and p75) or human TNF (binds only p55) inhibited OB differentiation. TNF did not inhibit OB differentiation in p55(-/-) MSC. Expression of p75 modestly attenuated sensitivity to TNF. To determine the role of apoptosis, changes in total DNA, cell viability, caspase 3, and percentage of annexin V-positive cells were measured in MSC and preosteoblastic MC3T3 cells. TNF treatment that reduced differentiation by 50% did not decrease cell viability or increase apoptosis, as determined by alamar blue reduction, trypan blue exclusion, and percentage of annexin V-positive cells. TNF increased caspase 3 activity 1.5-fold in MC3T3 and insignificantly in MSC cells compared with > 4-fold after 4 h actinomycin D. Treatment of MSC or MC3T3 cells with three caspase inhibitors failed to reverse the inhibitory effect of TNF on OB differentiation despite inhibition of caspase activity. These results suggest that the p55 receptor is essential, and p75 dispensable, for TNF inhibition of OB differentiation through a mechanism that does not require apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15625085     DOI: 10.1152/ajpendo.00534.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  52 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 2.  Role of NF-κB in the skeleton.

Authors:  Deborah Veis Novack
Journal:  Cell Res       Date:  2010-11-16       Impact factor: 25.617

3.  Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand.

Authors:  Jau-Yi Li; Hesham Tawfeek; Brahmchetna Bedi; Xiaoying Yang; Jonathan Adams; Kristy Y Gao; Majd Zayzafoon; M Neale Weitzmann; Roberto Pacifici
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts.

Authors:  Hiroyuki Kaneki; Ruolin Guo; Di Chen; Zhenqiang Yao; Edward M Schwarz; Ying E Zhang; Brendan F Boyce; Lianping Xing
Journal:  J Biol Chem       Date:  2005-12-22       Impact factor: 5.157

5.  Dose effect of tumor necrosis factor-alpha on in vitro osteogenic differentiation of mesenchymal stem cells on biodegradable polymeric microfiber scaffolds.

Authors:  Paschalia M Mountziaris; Stephanie N Tzouanas; Antonios G Mikos
Journal:  Biomaterials       Date:  2009-12-05       Impact factor: 12.479

6.  Functional PEG-peptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNFalpha.

Authors:  Chien-Chi Lin; Andrew T Metters; Kristi S Anseth
Journal:  Biomaterials       Date:  2009-06-27       Impact factor: 12.479

7.  Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.

Authors:  Héctor F Araya; Hugo Sepulveda; Carlos O Lizama; Oscar A Vega; Sofia Jerez; Pedro F Briceño; Roman Thaler; Scott M Riester; Marcelo Antonelli; Flavio Salazar-Onfray; Juan Pablo Rodríguez; Ricardo D Moreno; Martin Montecino; Martine Charbonneau; Claire M Dubois; Gary S Stein; Andre J van Wijnen; Mario A Galindo
Journal:  J Cell Biochem       Date:  2018-06-19       Impact factor: 4.429

Review 8.  Effects of anti-tumor necrosis factor α agents on bone.

Authors:  Vivian K Kawai; C Michael Stein; Daniel S Perrien; Marie R Griffin
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

9.  Direct bone formation during distraction osteogenesis does not require TNFalpha receptors and elevated serum TNFalpha fails to inhibit bone formation in TNFR1 deficient mice.

Authors:  Elizabeth C Wahl; James Aronson; Lichu Liu; Robert A Skinner; Mike J Miller; Gael E Cockrell; John L Fowlkes; Kathryn M Thrailkill; Robert C Bunn; Martin J J Ronis; Charles K Lumpkin
Journal:  Bone       Date:  2009-09-17       Impact factor: 4.398

10.  Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins.

Authors:  Ruolin Guo; Motozo Yamashita; Qian Zhang; Quan Zhou; Di Chen; David G Reynolds; Hani A Awad; Laura Yanoso; Lan Zhao; Edward M Schwarz; Ying E Zhang; Brendan F Boyce; Lianping Xing
Journal:  J Biol Chem       Date:  2008-06-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.